Nerdy Science Blog

CNNMoney

NEW YORK (Associated Press) - Biotech companies will likely be one of the few bright spots for investors this earnings season, as demand for essential medical treatments continues unabated despite the economic slowdown.

Large-cap biotechnology companies, whose shares have outperformed an overall weak market during the second quarter, are poised to meet or beat Wall Street profit forecasts, according to most analysts. Industry drug sales data has foreshadowed strong results for several key players.